

## News, current issues


News Exploration of diagnostic errors through Big Data >>

News Global cancer survival rates improve, but wide gaps remain >>

News Healthcare 2018: we found no indicator which shows good news >>


## Macro approach to financing healthcare and medicinal products

### Balance of the Health Insurance Fund, December 2017




## Dynamics of the sales/circulation of prescription-only-medicine


### Pharmacy DOT turnover




### Pharmacy reimbursement turnover



## Changes to subsidized medicinal product categories, December 2017



## Decision-making index, December 2017



Product offering

## Indicator system development

Quality indicators are needed to evaluate a therapy at macro level. The individual micro-level knowledge enables to seek/elaborate parameters which allow to build up an indicator system.

With the comprehensive knowledge acquired along our micro-level analysis products we can ensure elaboration of systems, which show the success of certain medical technologies in transparent way, with objective parameters.




Downloadable document:

[The domestic experiences of the „Changing Diabetes Barometer” program IME, 2011](#)


More about the service: [link](#)

## Market data

### Toplists of reimbursement and number of patients, December 2017




### Average number of medical sales reps



Source: NHIFA data, Healthware analysis

### TOP 10 active substances by number of patients (thousand patients)



## Analysis of published list of reimbursement submissions in 2017 – Case study

### Background

Present case study reports the analysis of the published list of reimbursement dossiers (of medicines and nutrients) received by the National Health Insurance Fund of Hungary (NHIF). Subjects of the analysis were dossiers that were submitted to NHIF in 2017 only.


### Method:

Method of the analysis was similar to the studies' published last years.<sup>1,2,3</sup> The results refer to end-2017 status.

### Results:


#### Number of reimbursement dossiers received by NHIF in 2017

In the year 2017, the National Health Insurance Fund received totally 279 submissions. Considering different drug formulations and dosages as one item, listing the brands, the number of submissions was 157 from 57 companies. Stratified for indication areas the number of these was 172.



### Distribution of decisions

Following graph illustrates the distribution of decisions. According to end-2017 status no rejective decision was made.




#### Number of reimbursed submissions compared to 2016


Rate of positive decision decreased compared to the last year by considering all submissions stratified by brands and indications.

### Initiation of procedures by month

Looking at the temporal distributions, most of the submissions arrived to the Payer in February and March (60-day submissions) and in July and November (90-day submissions). In other months of the year the average number of submissions were 8 and 5, respectively.



### Number of brands by reimbursement category



<sup>1</sup>Healthware Newsletter, No. 2, Issue III. 2015 February

<sup>2</sup>Healthware Newsletter, No. 2, Issue IV. 2016 February

<sup>3</sup>Healthware Newsletter, No. 1, Issue V. 2017 January

## Analysis of published list of reimbursement submissions in 2017 – Case study

### Agents with the most occurrences by type of reimbursement category and decision

		2017																		2016			2015								
		0% - Normative			25%,55%,80%- Normative			50%, 70%, 90%- Indication based			100%- Indication based			Special budget			Itemized			Hospital			SUM			SUM			SUM		
		Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed*	Reimbursed	Still on process	Not reimbursed**	Reimbursed	Still on process	Not reimbursed**
90-day submissions	Agents- TOP5/Total	1	2	1		3		1	7		2	16		1	3	1		29	1		1		5	61	3	30	54	5	30	51	4
	L01XC- Monoclonal antibodies																	8					8								
	L01XE- Protein kinase inhibitors										3							3					6								
	B02BD- Blood coagulation factors			1										1	2	1							1	2	2						
	L04AA- Selective immunosuppressants										2							2					4								
	L04AC- Interleukin inhibitors										1							2	1				3	1							
60-day submissions	Agents- TOP5/Total	6	1	1	29	9	2	28	3	3	28	1	2	1	1		1	2					93	17	8	108	12	10	126	3	11
	V06D- Nutrients	1			3	2		3			1												8	2							
	N02AX52- Tramadol	1		1	3		1				3		1										7		3						
	N06AX21- Duloxetine							5															5								
	J05AF10- Entecavir										2	1											2	1							
	L01XE01- Imatinib										3												3								

\*Extinctive decision, forced by the submitted company.

\*\*Extinctive decision, forced by the submitted company or rejected submission.

In case of the submissions with a 90 day evaluation period the most common reimbursement categories and reimbursed products were itemized and 100% indication based financing, and monoclonal antibodies, protein kinase inhibitors, respectively.

In case of 60-day submissions the most common reimbursement categories and reimbursed products were indication based and normative financing, and nutrients, psychoanalectics, respectively.

### 90 - 60 day submissions by ATC1 categories and years

ATC1	Name	90-day submissions			60-day submissions		
		2017	2016	2015	2017	2016	2015
A	Alimentary tract and metabolism	4	0	10	5	3	10
B	Blood and blood forming organs	10	9	5	6	3	5
C	Cardiovascular system	3	7	3	16	13	11
D	Dermatologicals	0	0	1	3	0	1
G	Genito-urinary system and sex hormones	0	2	7	2	1	4
H	Systemic hormonal preparations, excluding sex hormones and insulins	1	1	0	1	0	1
J	Antiinfectives for systemic use	1	7	7	18	19	12
L	Antineoplastic and immunomodulating agents	36	41	25	8	19	19
M	Musculo-skeletal system	1	4	3	6	5	2
N	Nervous system	3	5	6	20	35	38
R	Respiratory system	3	3	4	4	4	6
S	Sensory organs	2	1	7	2	0	2
V	Various	1	2	1	16	11	18